BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dos Santos EUD, Duarte EBC, Miranda LMR, Asano AGC, Asano NMJ, Maia MMD, de Souza PRE. Influence of DRD1 and DRD3 Polymorphisms in the Occurrence of Motor Effects in Patients with Sporadic Parkinson's Disease. Neuromolecular Med 2019;21:295-302. [PMID: 31119645 DOI: 10.1007/s12017-019-08549-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Akbar M, Soraya GV, Ulhaq ZS, Bintang AK. A Roadmap for Future Parkinson's Pharmacogenomics in Asia. Front Aging Neurosci 2022;14:896371. [DOI: 10.3389/fnagi.2022.896371] [Reference Citation Analysis]
2 Magistrelli L, Ferrari M, Furgiuele A, Milner AV, Contaldi E, Comi C, Cosentino M, Marino F. Polymorphisms of Dopamine Receptor Genes and Parkinson's Disease: Clinical Relevance and Future Perspectives. Int J Mol Sci 2021;22:3781. [PMID: 33917417 DOI: 10.3390/ijms22073781] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
3 Albarrán-Bravo S, Ávalos-Fuentes JA, Cortés H, Rodriguez-Sánchez M, Leyva-García N, Rangel-Barajas C, Erlij D, Florán B. Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects. Biomolecules 2019;9:E431. [PMID: 31480516 DOI: 10.3390/biom9090431] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]